Phase I trial of elactocin.

Elactocin is a novel anti-tumour antibiotic which has potent activity in vitro against a range of tumours. This phase I trial of elactocin identified the dose-limiting toxicity as profound anorexia and malaise. The schedules used included 1 h infusion 3 weekly, 24 h infusion 3 weekly, 1 h infusion d...

Descripción completa

Detalles Bibliográficos
Autores principales: Newlands, E. S., Rustin, G. J., Brampton, M. H.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1996
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074658/
https://www.ncbi.nlm.nih.gov/pubmed/8761384
_version_ 1782138013619322880
author Newlands, E. S.
Rustin, G. J.
Brampton, M. H.
author_facet Newlands, E. S.
Rustin, G. J.
Brampton, M. H.
author_sort Newlands, E. S.
collection PubMed
description Elactocin is a novel anti-tumour antibiotic which has potent activity in vitro against a range of tumours. This phase I trial of elactocin identified the dose-limiting toxicity as profound anorexia and malaise. The schedules used included 1 h infusion 3 weekly, 24 h infusion 3 weekly, 1 h infusion daily x 5 (3 weekly), 1 h infusion weekly and finally continuous 5 day intravenous infusion. On all these schedules dose-limiting toxicity was the same and as no partial or complete responses were identified, we do not recommend that further trials of elactocin are performed.
format Text
id pubmed-2074658
institution National Center for Biotechnology Information
language English
publishDate 1996
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20746582009-09-10 Phase I trial of elactocin. Newlands, E. S. Rustin, G. J. Brampton, M. H. Br J Cancer Research Article Elactocin is a novel anti-tumour antibiotic which has potent activity in vitro against a range of tumours. This phase I trial of elactocin identified the dose-limiting toxicity as profound anorexia and malaise. The schedules used included 1 h infusion 3 weekly, 24 h infusion 3 weekly, 1 h infusion daily x 5 (3 weekly), 1 h infusion weekly and finally continuous 5 day intravenous infusion. On all these schedules dose-limiting toxicity was the same and as no partial or complete responses were identified, we do not recommend that further trials of elactocin are performed. Nature Publishing Group 1996-08 /pmc/articles/PMC2074658/ /pubmed/8761384 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Newlands, E. S.
Rustin, G. J.
Brampton, M. H.
Phase I trial of elactocin.
title Phase I trial of elactocin.
title_full Phase I trial of elactocin.
title_fullStr Phase I trial of elactocin.
title_full_unstemmed Phase I trial of elactocin.
title_short Phase I trial of elactocin.
title_sort phase i trial of elactocin.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074658/
https://www.ncbi.nlm.nih.gov/pubmed/8761384
work_keys_str_mv AT newlandses phaseitrialofelactocin
AT rustingj phaseitrialofelactocin
AT bramptonmh phaseitrialofelactocin

Ejemplares similares